Results 211 to 220 of about 51,825 (261)
Some of the next articles are maybe not open access.
Cardiac Myosin Inhibitors: Expanding the Horizon for Hypertrophic Cardiomyopathy Management
Annals of Pharmacotherapy, 2023Objective: To review the current literature on the efficacy and safety of cardiac myosin inhibitors (CMIs) for the treatment of hypertrophic cardiomyopathy (HCM). Data Sources: A literature search was conducted on PubMed from origin to April 2023, using the search terms “MYK-461,” “mavacamten,” “CK-3773274,” and “aficamten.” Studies were limited to ...
Alyssa Sykuta +5 more
openaire +2 more sources
Current Opinion in Cardiology, 2023
Purpose of review Cardiac myosin inhibitors (CMIs) represent a major milestone in the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. The objective of this review is to discuss the mechanisms of action, clinical trial evidence, safety profile and monitoring of CMIs, which are important to the ...
Safia, Chatur, Sheila M, Hegde
openaire +2 more sources
Purpose of review Cardiac myosin inhibitors (CMIs) represent a major milestone in the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. The objective of this review is to discuss the mechanisms of action, clinical trial evidence, safety profile and monitoring of CMIs, which are important to the ...
Safia, Chatur, Sheila M, Hegde
openaire +2 more sources
Aficamten—A Second in Class Cardiac Myosin Inhibitor for Hypertrophic Cardiomyopathy
Cardiology in Review, 2023Hypertrophic cardiomyopathy is an under-recognized disease with a genetic component that results in abnormal and often asymmetric thickening of the left ventricle in addition to decreased compliance and progressive fibrosis of the myocardium. It further poses significant complications related to dynamic left ventricular outflow obstruction over time in
Jay, Patel +4 more
openaire +2 more sources
Mavacamten, a First-in-Class Cardiac Myosin Inhibitor for Obstructive Hypertrophic Cardiomyopathy
Annals of Pharmacotherapy, 2022Objective: To assess mavacamten’s role in hypertrophic cardiomyopathy treatment. Data Sources: In addition to clinical guidelines, package inserts, and general reviews, we searched PubMed using the term mavacamten from inception to June 11, 2022. Study Selection and Data Extraction: English language studies describing mavacamten’s mechanism of action ...
Joseph D. Dalo +2 more
openaire +2 more sources
Selective cardiac myosin inhibitors protect the heart following ischemia-reperfusion injury
European Heart Journal, 2023Abstract Background/Introduction Following an acute myocardial infarction, reperfusion of an occluded coronary artery is often accompanied by cardiomyocyte injury, leading to a worse long-term prognosis.
L Yusof, D M Yellon, S M Davidson
openaire +1 more source
First-in-class cardiac myosin inhibitor reduces symptoms of HCM
Nature Reviews Cardiology, 2020Mavacamten, a first-in-class cardiac myosin inhibitor, reduces symptoms and improves health status in patients with obstructive hypertrophic cardiomyopathy, according to findings from the EXPLORER-HCM trial.
openaire +2 more sources
Advances in Cardiovascular Pharmacotherapy. I. Cardiac Myosin Inhibitors
Journal of Cardiothoracic and Vascular AnesthesiaHypertrophic cardiomyopathy (HCM) is the most common inherited cardiomyopathy. The disease is characterized by asymmetric left ventricular (LV) remodeling with myocyte disarray and interstitial fibrosis, a hypercontractile state, dynamic subaortic obstruction of the LV outflow tract, impaired LV diastolic function, atrial and ventricular arrhythmias ...
Paul S, Pagel +3 more
openaire +2 more sources